Top

Published in:

01-01-2018 | Original Scientific Report

The Significance of Upfront Knowledge of N2 Disease in Non-small Cell Lung Cancer

Authors: Daniel C. Thomas, Brian N. Arnold, Joshua E. Rosen, Michelle C. Salazar, Frank C. Detterbeck, Justin D. Blasberg, Daniel J. Boffa, Anthony W. Kim

Published in: World Journal of Surgery | Issue 1/2018

Abstract

Background

Previous literature suggests that patients with non-small cell lung cancer (NSCLC) and unsuspected N2 disease (cN0, pN2) represent a distinct subgroup associated with improved overall survival compared to patients with N2 disease identified prior to resection (cN2, pN2).

Methods

Retrospective analysis of the National Cancer Database of patients from 2004 to 2011 with cN0 and cN2 status found to be pathologic stage III-N2 NSCLC after surgical resection. Comparison of 5-year survival of patients with unsuspected N2 disease versus those with known N2 disease after surgical resection using Kaplan–Meier analysis was made. The independent effect of unsuspected N2 disease on mortality was analyzed using multivariate analysis.

Results

A total of 3271 patients with pathologic stage III-N2 NSCLC underwent curative intent surgical resection with or without adjuvant chemotherapy or chemotherapy and radiation. Unsuspected N2 disease was identified in 48% of patients. Patients with unsuspected N2 disease were more likely to have T1 tumors (37 vs. 32%, p < 0.001). Unsuspected N2 disease did not impact 5-year overall survival compared with known N2 when adjuvant therapy was utilized (40 vs. 37%, p = 0.167). Multivariate analysis identified older age, higher comorbidity score, and treatment with surgery alone as independent risk factors for mortality. The presence of unsuspected N2 disease was not significant in this model.

Conclusions

The findings of this study suggest that unsuspected N2 disease is associated with equivalent 5-year survival compared to cN2 disease when adjuvant therapy is employed. These results support the use of adjuvant chemotherapy and radiation therapy when confronted with unsuspected N2 disease after surgical resection for stage IIIA-NSCLC.

Available only for authorised users

Howington JA, Blum MG, Chang AC et al (2013) Treatment of stage I and II non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143:e278S–e313SCrossRefPubMed

Detterbeck F (2008) What to do with “Surprise” N2?: intraoperative management of patients with non-small cell lung cancer. J Thorac Oncol 3:289–302CrossRefPubMed

Andre F, Grunenwald D, Pignon J-P et al (2000) Survival of patients with resected N2 non–small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol 18:2981–2989CrossRefPubMed

Sakao Y, Miyamoto H, Yamazaki A et al (2006) Prognostic significance of metastasis to the highest mediastinal lymph node in nonsmall cell lung cancer. Ann Thorac Surg 81:292–297CrossRefPubMed

Yang C-FJ, Kumar A, Gulack BC et al (2016) Long-term outcomes after lobectomy for non–small cell lung cancer when unsuspected pN2 disease is found: a national cancer data base analysis. J Thorac Cardiovasc Surg 151:1380–1388CrossRefPubMed

Ichinose Y, Kato H, Koike T et al (2001) Overall survival and local recurrence of 406 completely resected stage IIIa-N2 non-small cell lung cancer patients: questionnaire survey of the Japan clinical oncology group to plan for clinical trials. Lung Cancer 34:29–36CrossRefPubMed

Vansteenkiste JF, De Leyn PR, Deneffe GJ et al (1997) Survival and prognostic factors in resected N2 non-small cell lung cancer: a study of 140 cases. Ann Thorac Surg 63:1441–1450CrossRefPubMed

Bott MJ, Patel AP, Crabtree TD et al (2015) Pathologic upstaging in patients undergoing resection for stage I non-small cell lung cancer: are there modifiable predictors? Ann Thorac Surg 100:2048–2053CrossRefPubMedPubMedCentral

Vansteenkiste JF, De Leyn PR, Deneffe GJ et al (1998) Clinical prognostic factors in surgically treated stage IIIA-N2 non-small cell lung cancer: analysis of the literature. Lung Cancer 19:3–13CrossRefPubMed

10.

Ettinger DS, Wood DE, Akerley W et al (2014) Non-small cell lung cancer, version 1.2015. J Natl Compr Cancer Netw 12:1738–1761CrossRef

11.

American Joint Committee on Cancer, American Cancer Society. AJCC cancer staging manual. 6th ed. Available at http://cancerstaging.org/references-tools/quickreferences/ documents/lungmedium.pdf. Accessed Oct 2015

12.

Boffa DJ, Hancock JG, Yao X et al (2015) Now or later: evaluating the importance of chemotherapy timing in resectable stage III (N2) lung cancer in the National Cancer Database. Ann Thorac Surg 99:200–208CrossRefPubMed

13.

Rocco G, Nason K, Brunelli A et al (2016) Management of stage IIIA (N2) non–small cell lung cancer: a transatlantic perspective. J Thorac Cardiovasc Surg 151:1235–1238CrossRefPubMed

14.

Lerro C, Robbins A, Phillips J et al (2013) Comparison of cases captured in the national cancer data base with those in population-based central cancer registries. Ann Surg Oncol 20:1759–1765CrossRefPubMed

15.

Boffa DJ, Allen MS, Grab JD et al (2008) Data from the society of thoracic surgeons general thoracic surgery database: the surgical management of primary lung tumors. J Thorac Cardiovasc Surg 135:247–254CrossRefPubMed

16.

Daly BD, Mueller JD, Faling LJ et al (1993) N2 lung cancer: outcome in patients with false-negative computed tomographic scans of the chest. J Thorac Cardiovasc Surg 105:904–910 discussion 910–901 PubMed

17.

Sakao Y, Miyamoto H, Yamazaki A et al (2006) The spread of metastatic lymph nodes to the mediastinum from left upper lobe cancer: results of superior mediastinal nodal dissection through a median sternotomy. Eur J Cardiothorac Surg 30:543–547CrossRefPubMed

18.

Tanaka F, Yanagihara K, Otake Y et al (2004) Prognostic factors in resected pathologic (p-) stage IIIA-N2, non-small-cell lung cancer. Ann Surg Oncol 11:612–618CrossRefPubMed

19.

Tsitsias T, Boulemden A, Ang K et al (2014) The N2 paradox: similar outcomes of pre- and postoperatively identified single-zone N2a positive non-small-cell lung cancer. Eur J Cardiothorac Surg 45:882–887CrossRefPubMed

20.

Silvestri GA, Gonzalez AV, Jantz MA et al (2013) Methods for staging non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: american college of chest physicians evidence-based clinical practice guidelines. Chest 143:e211S–e250SCrossRefPubMed

21.

Rosell R, Gomez-Codina J, Camps C et al (1994) A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 330:153–158CrossRefPubMed

22.

Roth JA, Fossella F, Komaki R et al (1994) A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 86:673–680CrossRefPubMed

23.

van Meerbeeck JP, Kramer GW, Van Schil PE et al (2007) Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst 99:442–450CrossRefPubMed

24.

Albain KS, Swann RS, Rusch VW et al (2009) Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. The Lancet 374:379–386CrossRef

25.

Thomas M, Rübe C, Hoffknecht P et al (2008) Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. Lancet Oncol 9:636–648CrossRefPubMed

26.

Boffa DJ, Kosinski AS, Paul S et al (2012) Lymph node evaluation by open or video-assisted approaches in 11,500 anatomic lung cancer resections. Ann Thorac Surg 94:347–353CrossRefPubMed

27.

D’Amico TA, Niland J, Mamet R et al (2011) Efficacy of mediastinal lymph node dissection during lobectomy for lung cancer by thoracoscopy and thoracotomy. Ann Thorac Surg 92:226–232CrossRefPubMed

Title: The Significance of Upfront Knowledge of N2 Disease in Non-small Cell Lung Cancer
Authors: Daniel C. Thomas
Brian N. Arnold
Joshua E. Rosen
Michelle C. Salazar
Frank C. Detterbeck
Justin D. Blasberg
Daniel J. Boffa
Anthony W. Kim
Publication date: 01-01-2018
Publisher: Springer International Publishing
Published in: World Journal of Surgery / Issue 1/2018
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI: https://doi.org/10.1007/s00268-017-4165-6

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The Significance of Upfront Knowledge of N2 Disease in Non-small Cell Lung Cancer

Abstract

Background

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2018

A Prospective Study of 7-Year Experience Using Percutaneous 14-French Pigtail Catheters for Traumatic Hemothorax/Hemopneumothorax at a Level-1 Trauma Center: Size Still Does Not Matter

Burr-Hole Craniostomy for Chronic Subdural Hematomas by General Surgeons in Rural Kenya

Hospital Workload for Weapon-Wounded Females Treated by the International Committee of the Red Cross: More Work Needed than for Males

Younger Age is an Independent Factor for Graft Weight Overestimation: Analysis of the Clinical Impact on Recipient Outcomes in 340 Japanese Living Liver Donors

Histologically Proven Bronchial Neuroendocrine Tumors in MEN1: A GTE 51-Case Cohort Study

A Novel Lateral Approach to the Assessment of Vocal Cord Movement by Ultrasonography